Xbrane Biopharma AB (publ) (STO:XBRANE)

Xbrane Biopharma AB Ratios and Metrics

Market cap in millions SEK. Fiscal year is January - December.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	May 21, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Market Capitalization	240	210	246	297	2,258	2,624
Market Cap Growth	-19.66%	-14.54%	-17.28%	-86.83%	-13.94%	58.03%
Enterprise Value	230	117	386	371	2,133	2,285
Last Close Price	11.65	10.20	20.10	1250.00	10262.50	13100.00
PE Ratio	2.26	1.65	-	-	-	-
Forward PE	-	-	18.40	-	-	-
PS Ratio	3.14	1.38	1.66	1.25	39.19	245.04
PB Ratio	0.44	0.38	1.18	1.74	5.32	6.08
P/TBV Ratio	0.44	0.38	1.18	1.74	5.32	6.08
EV/Sales Ratio	3.01	0.77	2.60	1.56	37.03	213.37
Debt / Equity Ratio	0.10	0.10	0.92	1.35	0.09	0.10
Net Debt / Equity Ratio	-0.02	-0.05	0.32	0.97	-0.37	-0.58
Net Debt / EBITDA Ratio	0.17	1.44	-0.92	-0.58	1.07	1.46
Net Debt / FCF Ratio	0.05	0.11	-0.50	-0.40	0.76	1.01
Asset Turnover	0.11	0.20	0.20	0.36	0.08	0.02
Inventory Turnover	0.16	0.28	0.10	2.59	-	-
Quick Ratio	0.79	2.43	0.40	0.42	1.02	1.84
Current Ratio	3.03	7.12	1.13	1.41	2.17	2.55
Return on Equity (ROE)	-20.41%	-12.00%	-74.40%	-108.02%	-39.34%	-53.15%
Return on Assets (ROA)	-5.20%	-1.65%	-6.88%	-27.60%	-13.84%	-19.14%
Return on Capital Employed (ROCE)	-10.30%	-3.20%	-27.00%	-90.80%	-33.60%	-37.60%
Earnings Yield	44.16%	60.54%	-108.25%	-130.56%	-7.64%	-7.18%
FCF Yield	-	-119.28%	-54.58%	-139.07%	-9.10%	-9.42%
Buyback Yield / Dilution	94.75%	-67.03%	-4184.59%	-12.26%	-8.38%	-30.25%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.